Publication: Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis
Issued Date
2019-06-01
Resource Type
ISSN
18790305
13596101
13596101
Other identifier(s)
2-s2.0-85065891428
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cytokine and Growth Factor Reviews. Vol.47, (2019), 43-53
Suggested Citation
Wanvisa Udomsinprasert, Jiraphun Jittikoon, Sittisak Honsawek Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis. Cytokine and Growth Factor Reviews. Vol.47, (2019), 43-53. doi:10.1016/j.cytogfr.2019.05.005 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50162
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis
Other Contributor(s)
Abstract
© 2019 Elsevier Ltd Interleukin-34 (IL-34), recently identified as a novel inflammatory cytokine and the second ligand for colony-stimulating factor-1 receptor, is known to play regulatory roles in the development, maintenance, and function of mononuclear phagocyte lineage cells – especially osteoclasts. Regarding its primary effect on osteoclasts, IL-34 has been shown to stimulate formation and activation of osteoclasts, which in turn magnifies osteoclasts-resorbing activity. In addition to its role in osteoclastogenesis, IL-34 has been implicated in inflammation of synovium via augmenting production of inflammatory mediators, in which altered IL-34 expression is regulated by pro-inflammatory cytokines responsible for cartilage degradation. Indeed, IL-34 has been documented to be highly expressed in inflamed synovium of rheumatoid arthritis (RA) and knee osteoarthritis (OA) patients, which are recognized as inflammatory arthritis. Furthermore, a number of clinical studies demonstrated that IL-34 levels were significantly increased in the circulation and synovial fluid of patients with RA and knee OA. Its levels were also found to be positively associated with disease severity – especially radiographic severity of both RA and knee OA patients. Interestingly, emerging evidence has accumulated that functional blockage of IL-34 with specific antibody can alleviate the severity of inflammatory arthritis. It is therefore reasonable to speculate that IL-34 may be developed as a potential biomarker and a new therapeutic candidate for inflammatory arthritis. To date, there are numerous studies showing IL-34 involvement and association with many aspects of inflammatory arthritis. Herein, this review aimed to summarize the recent findings regarding regulatory role of IL-34 in synovial inflammation-mediated cartilage destruction and update the current comprehensive knowledge on usefulness of IL-34-based treatment in inflammatory arthritis – particularly RA and knee OA.